Asia Weighed by Trump Tariff Threats
Asia-Pacific markets fell Thursday, as investors weighed U.S. President Donald Trump’s proposed tariffs on autos, chips and pharmaceutical imports as well as the Federal Reserve potentially keeping rates higher for longer.Trump, who said the duties could be implemented as soon as April 2, did not specify whether they will be targeted at imports from certain countries or be broad-based.In Japan, the Nikkei 225 index dumped 486.57 points, or 1.2%, to 38,678.04.The yen rose to a more than two-month high of 150.52 per U.S. dollar earlier in the day amid bets of more rate hikes by the Bank of Japan this year.In Hong Kong, the Hang Seng index dropped 367.26 points, or 1.6%, to 22,576.98. Australian markets shared in the downward trend. 1.15% lower at 8,322.80.The country’s seasonally adjusted unemployment rate rose to 4.1% in January, in line with Reuters’ estimates.In other marketsThe CSI 300 in mainland China backpedaled 11.26 points, or 0.3% to 3,928.90In Taiwan, the Taiex index shed 116.62 points, or 0.5%, to 23,487.46.In Singapore, the Straits Times index gave back 6.53 points, or 0.2%, to 3,927.51In Korea, the Kospi index deleted 17.46 points, or 0.7%, to 2,654.06.In New Zealand, the NZX 50 subtracted 153 points, or 1.2%, to 12,880.36In Australia, the ASX 200 surrendered 96.37 points, or 1.1%, to 8,322.82.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


